Related Experiment Videos
Leucine enkephalin degradation in allergopathic versus normal human plasma
L Bongiorno1, L Fuso, M Marini
1Dipartimento di Medicina Sperimentale, Università degli Studi di Roma Tor Vergata, Rome, Italy.
Immunopharmacology
|August 26, 1998
Summary
Allergopathic patients show reduced enzyme hydrolysis of leu-enkephalin, with altered by-product patterns compared to controls. These changes are significant in both acute and quiescent stages, linked to enzyme activity and plasma inhibitors.
Area of Science:
- Biochemistry
- Enzymology
- Clinical Chemistry
Background:
- Enzyme hydrolysis of peptides like leu-enkephalin is crucial for biological processes.
- Allergopathic conditions may involve altered plasma enzyme activity and inhibitor profiles.
- Understanding these changes is vital for diagnosing and managing allergic diseases.
Purpose of the Study:
- To investigate the enzyme hydrolysis of leu-enkephalin in allergopathic patients.
- To compare hydrolysis patterns in acute and quiescent stages versus healthy controls.
- To identify biochemical markers associated with allergopathic conditions.
Main Methods:
- Kinetic and chromatographic techniques were employed.
- Hydrolysis of labelled leu-enkephalin was studied in plasma.
- Statistical analysis using ANOVA was performed on patient data.
Main Results:
- Substrate degradation of leu-enkephalin was reduced in allergopathic patients.
- Hydrolysis by-product patterns were significantly modified in both acute and quiescent stages.
- Reduced enzyme activity and increased low molecular weight plasma inhibitors were observed.
Conclusions:
- A distinct leu-enkephalin hydrolysis pattern characterizes allergopathic subjects.
- This pattern is associated with decreased enzyme activity and increased plasma inhibitors.
- The findings suggest potential diagnostic biomarkers for allergopathic diseases.